Last Updated: 27/05/2025
Malaria Vaccines: transmission blocking vaccine (TBV) Antigens as Conjugates with Alternate Carriers
Objectives
Evaluation of outer membrane protein complex (OMPC) as a delivery platform for TBV antigens synthesizing several conjugates of Pfs25 and Pfs230 by two different synthetic methods and with varying levels of antigen load, to investigate the effect of these parameters on the immunogenicity of the conjugates.
Plasmodium falciparum malaria and typhoid fever, which are co-endemic in many parts of the world, particularly in tropical areas, therefore developing a Bivalent Conjugate Vaccine Candidate against both would be very interesting. Protein-protein conjugate nanoparticles for malaria antigen delivery and enhanced immunogenicity Chemical conjugation of polysaccharide to carrier proteins has been a successful strategy to generate potent vaccines against bacterial pathogens. We developed a similar approach for poorly immunogenic malaria protein antigens. Our lead candidates in clinical trials are the malaria transmission-blocking vaccine antigens, Pfs25 and Pfs230D1, individually conjugated to the carrier protein Exoprotein A (EPA) through thioether chemistry.
Jan 2007 — Dec 2018
$9.24M
Related Resources
